Vivacelle’s VBI-S is designed to treat hypovolemic patients in urgent need of care due to septic shock
Septic shock impacts approximately two million people in the U.S. each year, the leading cause of hospital-related mortality and a major financial burden for the medical system
KANSAS CITY, Mo., July 23, 2024 /PRNewswire/ — Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced the initiation of a Phase 3 trial for its lead therapeutic candidate, VBI-S, to treat hypovolemic septic shock, a leading cause of death that impacts millions globally. VBI-S is built on the company’s pioneering and patented phospholipid nanoparticle technology, which leverages the redistribution of nitric oxide to elevate blood pressure in patients with hypovolemic septic shock.
